<DOC>
	<DOCNO>NCT01189435</DOCNO>
	<brief_summary>The purpose study measure ability erlotinib effectively treat recurrent lung cancer carry EGFR mutation lung cancer prior treatment erlotinib gefitinib receive post-surgical post-radiation setting .</brief_summary>
	<brief_title>Erlotinib Re-Challenge Recurrent EGFR-mutant Lung Cancer Patients Who Previously Received Adjuvant Erlotinib Gefitinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>A history stage IIIIB NSCLC Previously underdone definitive surgery radiation Received prior adjuvant treatment neoadjuvant erlotinib gefitinib total least 3 month time Stopped adjuvant erlotinib neoadjuvant least 2 month prior date first image demonstrate recurrence Pathologic evidence recurrent lung cancer , confirm MSKCC EGFR sensitize mutation ( point mutation exon 18 21 , deletion exon 19 ) must document primary recurrent tumor Tissue recurrent tumor must submit EGFR mutation testing , evaluate presence T790M mutation ( result need report eligible ) Measurable disease RECIST ; receive prior irradiation , must target lesion outside irradiated field Signed informed consent Age &gt; = 21 year old Persons reproductive potential must agree use adequate method contraception throughout treatment least 4 week study drug stop Prior progressive disease receive erlotinib gefitinib therapy Patients know preexist interstitial lung disease Total bilirubin great 1.8 mg/dl , except patient know Gilbert 's syndrome AST ALT great five time upper limit normal Pregnant lactate woman Medically unfit erlotinib therapy determine treat oncologist</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>OSI-774 , TARCEVA ( ERLOTINIB )</keyword>
	<keyword>Lung</keyword>
	<keyword>recurrent</keyword>
	<keyword>10-097</keyword>
	<keyword>Gefitinib</keyword>
</DOC>